The relationship between level of anti-CCP, clinical activity and quality of life in patients with psoriatic arthritis

Abstract

Objectives: Psoriatic arthritis (PsA) is an inflammatory joint disease. The aim of this study was to investigate the titers of Anti-syclic citrullinated protein (anti-CCP antibodies) in PsA and assess their associations with clinical characteristics and quality of life. Materials and methods: Fourty two patients with PsA and 38 healthy control subjects were included. Demographic data and clinical characteristics including age, gender, disease duration, and erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), anti-CCP antibodies and rheumatoid factor were assessed. Visual analog scale (VAS), Nottingham Health Profile (NHP) and short form-36 (SF-36) were used to evaluate QOL in both groups. Results: The demographic data of the subjects were not different between the groups. Patients with PsA had higher anti-CCP levels compared to healthy controls (56.3±73.0 U vs. 0.9±0.5 U, respectively, p=0.01) Thirteen (33.3%) patients with PsA had positive anti-CCP, while no anti-CCP positivity was found in the control group (p

Keywords

• Psoriatic arthritis (PsA), Anti-syclic citrullinated protein (anti-CCP) antibodies, quality of life.

Psoriatik artritli hastalarda anti-CCP düzeyi ile klinik aktivite ve yaşam kalitesi arasındaki ilişki

Öz

Amaç: Psoriatik artrit (PsA); psoriasis ile ilişkili bir kronik inflamatuar eklem hastalığıdır. Bu çalışmada PsA'lı hastalarda Anti-siklik sitrülenmiş protein (anti-CCP) düzeyi ile klinik aktivite ve yaşam kalitesi arasındaki ilişkinin araştırılması amaçlanmıştır. Gereç ve yöntem: Çalışmaya 42 PsA hastası çalışma grubu ve 38 sağlıklı birey kontrol grubu olarak alındı. Demografik ve klinik özellikler; yaş, cinsiyet, hastalık süresi, Eritrosit sedimantasyon hızı (ESH), C-reaktif protein (CRP), anti-CCP antikorları, RF ve vizual ağrı skalası (VAS) ile periferik eklem ağrısı değerlendirildi. Nottingham Sağlık Profili (NHP) ve Short form-36 (SF-36) her iki grupta yaşam kalitesini değerlendirmek için kullanıldı. Bulgular: Gruplar arasındaki demografik özellikler farklı değildi. Anti-CCP antikor düzeyleri PsA hastalarında (56.3±73.0 Ünite) kontrol grubuyla (0.9±0.5 Ünite) karşılaştırıldığında anlamlı yüksek bulundu (p=0.01). Anti-CCP antikoru pozitif birey sayısı PsA'li hasta grubunda kontrol grubuna göre anlamlı olarak yüksekti (%33.3 hastaya karşılık %0) (p

Anahtar Kelimeler

• Psoriatik artrit, Anti-siklik sitrülenmiş protein (anti-CCP) antikoru, yaşam kalitesi

Kaynakça

1. Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W. The health-related quality of life in rheumatoid arthritis, ankylo- sing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Out- comes 2009;7(1):25-9.
2. Schellekens GA, Visser H, de Jong BA, et al. The diag- nostic properties of rheumatoid arthritis antibodies rec- ognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43(1):155-63.
3. Bogliolo L, Alpini C, Caporali R, Scire CA, Moratti R, Mon- tecucco C. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005;32(3):511-5.
4. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: de- velopment of new criteria from a large international study. Arthritis Rheum 2006;54(8):2665-73.
5. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoan- tibodies in patients with synovitis of recent onset. Arthritis Res 2000;2(3):236-43.
6. Korendowych E, Owen P, Ravindran J, Carmichael C, McHugh N. The clinical and genetic associations of anti- cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 2005;44(8):1056-60.
7. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Pso- riatic arthritis (PA): a clinical, immunological and radiolog- ical study of 180 patients. Br J Rheumatol 1991;30(4):245- 50.
8. Abdel Fattah NS, Hassan HE, Galal ZA, El Okda el SE. As- sessment of anti-cyclic citrullinated peptide in psoriatic ar- thritis. BMC Res Notes 2009;2(1):44-5.

9. Alenius GM, Jidell E, Nordmark L, Rantapaa Dahlqvist S. Disease manifestations and HLA antigens in psoriatic ar- thritis in northern Sweden. Clin Rheumatol 2002;21(5):357- 62.
10. Zink A, Thiele K, Huscher D, et al. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheu- matoid arthritis and ankylosing spondylitis. J Rheumatol 2006;33(1):86-90.
11. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheu- matol 2001;28(8):1842-6.
12. Borman P, Toy GG, Babaoglu S, Bodur H, Ciliz D, Alli N. A comparative evaluation of quality of life and life satisfac- tion in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol 2007;26(3):330-4.
13. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health- related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthri- tis Rheum 2001;45(2):151-8.
14. Husted JA, Tom BD, Schentag CT, Farewell VT, Gladman DD. Occurrence and correlates of fatigue in psoriatic arthri- tis. Ann Rheum Dis 2009;68(10):1553-8.
15. Gladman DD, Mease PJ, Krueger G, van der Heidje DM, Antoni C, Helliwell PS, et al. Outcome measures in psori- atic arthritis. J Rheumatol 2005;32(11):2262-9.
16. Alenius GM, Berglin E, Rantapaa Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic pa- tients with or without joint inflammation. Ann Rheum Dis 2006;65(3):398-400.
17. Candia L, Marquez J, Gonzalez C, et al. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J Clin Rheumatol 2006;12(5):226-9.
18. Inanc N, Dalkilic E, Kamali S, et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007;26(1):17-23.
19. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses’ Health Study II. Am J Med 2007;120(11):953-9.
20. Vander Cruyssen B, Hoffman IE, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic ar- thritis. Ann Rheum Dis 2005;64(8):1145-9.